Illustration: Assistant Editor Kathy Wong for Endpoints News
January 17, 2023 12:37 PM EST
Pharma
Marketing

Drug name re­view: Sci­ence takes the spot­light in 2022

Beth Snyder Bulik

Senior Editor

Sci­ence was the name of the game in phar­ma drugs last year — lit­er­al­ly. FDA-ap­proved drug names in 2022 leaned heav­i­ly on sci­ence as­so­ci­a­tions, ac­cord­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times